Shan Ying, Zheng Jianyu, Lambrecht Richard W, Bonkovsky Herbert L
Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA.
Gastroenterology. 2007 Oct;133(4):1166-74. doi: 10.1053/j.gastro.2007.08.002. Epub 2007 Aug 3.
BACKGROUND & AIMS: Heme oxygenase-1 (HO-1) is an antioxidant defense and key cytoprotective enzyme, which is repressed by Bach1. Micro-RNA-122 (miR-122) is specifically expressed and highly abundant in human liver and required for replication of hepatitis C virus (HCV) RNA. This study was to assess whether a specific miR-122 antagomir down-regulates HCV protein replication and up-regulates HO-1.
We transfected antagomir of miR-122, 2'-O-methyl-mimic miR-122, or nonspecific control antagomir, into wild-type (WT) Huh-7 cells or Huh-7 stably replicating HCV subgenomic protein core through nonstructural protein 3 of HCV (NS3) (CNS3 replicon cells) or NS3-5B (9-13 replicon cells).
Antagomir of miR-122 reduced the abundance of HCV RNA by 64% in CNS3 and by 84% in 9-13 cells. Transfection with 2'-O-methlyl-mimic miR-122 increased HCV levels up to 2.5-fold. Antagomir of miR-122 also decreased Bach1 and increased HO-1 mRNA levels in CNS3, 9-13, and WT Huh-7 cells. Increasing HO-1 by silencing Bach1 with 50 nmol/L Bach1-short interfering RNA or by treatment with 5 mumol/L cobalt protoporphyrin or heme (known inducers of HO-1) decreased HCV RNA and protein by 50% in HCV replicon cells.
Down-regulation of HCV replication using an antagomir targeted to miR-122 is effective, specific, and selective. Increasing HO-1, by silencing the Bach1 gene or by treatment with cobalt protoporphyrin or heme, decreases HCV replication. Thus, miR-122 plays an important role in the regulation of HCV replication and HO-1/Bach1 expression in hepatocytes. Down-regulation of miR-122 and up-regulation of HO-1 may be new strategies for anti-HCV intervention and cytoprotection.
血红素加氧酶-1(HO-1)是一种抗氧化防御和关键的细胞保护酶,受Bach1抑制。微小RNA-122(miR-122)在人肝脏中特异性表达且含量丰富,是丙型肝炎病毒(HCV)RNA复制所必需的。本研究旨在评估特异性miR-122拮抗剂是否能下调HCV蛋白复制并上调HO-1。
我们将miR-122拮抗剂、2'-O-甲基模拟miR-122或非特异性对照拮抗剂转染到野生型(WT)Huh-7细胞或通过HCV非结构蛋白3(NS3)稳定复制HCV亚基因组蛋白核心的Huh-7细胞(CNS3复制子细胞)或NS3-5B(9-13复制子细胞)中。
miR-122拮抗剂使CNS3细胞中的HCV RNA丰度降低64%,9-13细胞中降低84%。用2'-O-甲基模拟miR-122转染使HCV水平提高至2.5倍。miR-122拮抗剂还降低了CNS3、9-13和WT Huh-7细胞中的Bach1水平并提高了HO-1 mRNA水平。在HCV复制子细胞中,用50 nmol/L Bach1小干扰RNA沉默Bach1或用5 μmol/L钴原卟啉或血红素(已知的HO-1诱导剂)处理来增加HO-1,可使HCV RNA和蛋白降低50%。
使用靶向miR-122的拮抗剂下调HCV复制是有效、特异且有选择性的。通过沉默Bach1基因或用钴原卟啉或血红素处理来增加HO-1可降低HCV复制。因此,miR-122在肝细胞中HCV复制及HO-1/Bach1表达的调控中起重要作用。下调miR-122和上调HO-1可能是抗HCV干预和细胞保护的新策略。